Cardiac Rehabilitation for the Treatment of Refractory Angina

Sponsor
National Heart and Lung Institute (Other)
Overall Status
Completed
CT.gov ID
NCT00411359
Collaborator
British Heart Foundation (Other), Royal Brompton & Harefield NHS Foundation Trust (Other)
42
1
2
40
1.1

Study Details

Study Description

Brief Summary

The purpose of this study is to determine whether cardiac rehabilitation is a successful treatment for refractory angina, in relation to improvements in cardiovascular risk factors, physical ability, symptomology, quality of life and psychological morbidity.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cardiac rehabilitation
Phase 3

Detailed Description

The majority of patients presenting with angina pectoris resulting from coronary artery disease (CHD) are successfully treated with interventions including coronary artery bypass grafting (CABG) and percutaneous transluminal coronary angioplasty (PTCA) and medical management. However, a growing number of patients experience persistent angina in spite of intervention and optimal medical treatment. Such patients are referred to as suffering from 'refractory angina'.

Currently, cardiac rehabilitation centres are reluctant to accept patients with ongoing angina or complicated cardiovascular history, in spite of the duration or stability of the symptoms. Indeed, angina and heart failure are often used to exclude patients from cardiac rehabilitation. However, in the recent updated American Heart Association (AHA) recommendations for exercise and training, cardiac rehabilitation and supervised exercise training is recommended for patients with ongoing angina, previous history of CABG, MI, PTCA and patients with existing cardiomyopathy in order to promote a reduction in myocardial ischaemia at rest and during sub-maximal exercise, while reducing the risk for the progression of CHD. Nevertheless, studies exploring the physiological and psychological impact of routinely available CR as a stand-alone intervention among refractory angina patients have not previously been undertaken. Until such studies are performed, CR practitioners will continue to refuse to accept refractory angina patients for participation in CR.

Research questions:
  • Is an eight-week cardiac rehabilitation exercise programme an appropriate treatment option for patients with refractory angina?

  • Does an eight-week cardiac rehabilitation exercise programme improve the physical functioning and cardiovascular health of patients with refractory angina?

  • Is symptom severity and frequency reduced following an eight-week cardiac rehabilitation exercise programme in patients with refractory angina?

  • Does an eight-week cardiac rehabilitation exercise programme have any impact on anxiety, depression, cardiac anxiety and quality of life in patients with refractory angina?

  • Are any physiological or psychological effects acquired by patients with refractory angina participating in a cardiac rehabilitation exercise programme maintained at an eight-week follow-up?

The study is conceived as a randomised intervention-control study of a standard, routinely available Phase III hospital-based CR program among patients with refractory angina. Patients will be randomly assigned to an eight-week CR programme based at Harefield Hospital or symptom diary monitoring control group.

Study Design

Study Type:
Interventional
Actual Enrollment :
42 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Cardiac Rehabilitation for the Treatment of Refractory Angina
Study Start Date :
Dec 1, 2006
Actual Primary Completion Date :
Dec 1, 2009
Actual Study Completion Date :
Apr 1, 2010

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cardiac rehabilitation

8-week cardiac rehabilitation programme

Behavioral: Cardiac rehabilitation
Phase III cardiac rehabilitation programme

No Intervention: Monitoring

Carry on life as normal

Outcome Measures

Primary Outcome Measures

  1. Health anxiety [Base, week 8 (post intervention/monitoring), week 16 (8 weeks post intervention/monitoring)]

    Health anxiety questionnaire (HAQ)

  2. Generalised anxiety and depression [Base, week 8 (post intervention/monitoring), week 16 (8 weeks post intervention/monitoring)]

    Hospital Anxiety and Depression scale (HADS)

Secondary Outcome Measures

  1. Systolic and diastolic blood pressure [Base, week 8 (post intervention/monitoring), week 16 (8 weeks post intervention/monitoring)]

    Measured after 10 minutes sitting, using automated machine (eg. Omron machine)

  2. Heart rate [Base, week 8 (post intervention/monitoring), week 16 (8 weeks post intervention/monitoring)]

    Heart rate measured using automated machine (eg. Omron blood pressure machine) or manually at the radial pulse

  3. Anthropomometry [Base, week 8 (post intervention/monitoring), week 16 (8 weeks post intervention/monitoring)]

    Weight, height, waist circumference (tape measure), hip circumference (tape measure), body mass index calculated from height and weight using the following website: http://www.nhlbisupport.com/bmi/bmi-m.htm

  4. Fasting lipids [Base, week 8 (post intervention/monitoring), week 16 (8 weeks post intervention/monitoring)]

    total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides. Measured in biochemistry departments of the Royal Brompton & Harefield NHS Foundation Trust using standard techniques.

  5. Social support [Baseline]

    Measured using the ENRICHED social support instrument (ESSI)

  6. Angina related health beliefs [Base, week 8 (post intervention/monitoring), week 16 (8 weeks post intervention/monitoring)]

    Measured using the York angina beliefs scale.

  7. Physical activity and exercise capacity [Base, week 8 (post intervention/monitoring), week 16 (8 weeks post intervention/monitoring)]

    Progressive shuttle walk test

  8. Angina frequency and severity [Base, week 8 (post intervention/monitoring), week 16 (8 weeks post intervention/monitoring)]

    Subjects completed a daily symptom monitoring diary

  9. Quality of life [Base, week 8 (post intervention/monitoring), week 16 (8 weeks post intervention/monitoring)]

    SF-36 quality of life scale

  10. Plasma glucose [Base, post intervention/monitoring, 8 weeks post intervention/monitoring]

    Measured in the biochemistry departments of the Royal Brompton & Harefield NHS Foundation Trust using standard techniques.

  11. Urea & electrolytes [Base, post intervention/monitoring, 8 weeks post intervention/monitoring]

    Measured in the biochemistry departments of the Royal Brompton & Harefield NHS Foundation Trust using standard techniques

  12. Liver function tests [Baseline, post intervention/monitoring, 8 weeks post intervention/monitoring]

    Measured in the biochemistry departments of the Royal Brompton & Harefield NHS Foundation Trust using standard techniques.

  13. Thyroid function tests [Baseline, post intervention/monitoring, 8 weeks post intervention/monitoring]

    Measured in the biochemistry departments of the Royal Brompton & Harefield NHS Foundation Trust using standard techniques.

  14. Hb [Baseline, post intervention/monitoring, 8 weeks post intervention/monitoring]

    Measured in the haematology departments of the Royal Brompton & Harefield NHS Foundation Trust using standard techniques.

  15. HbA1C (if diabetic) [Baseline, post intervention/monitoring, 8 weeks post intervention/monitoring]

    Measured in the haematology department of the Royal Brompton & Harefield NHS Foundation Trust using standard techniques

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Clinically diagnosed with refractory angina > 6 months

  • Two or more episodes of angina per week

  • Males and females aged 30 - 80

  • Previous history of single or multiple myocardial infarction (MI), coronary artery bypass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA) or any combination of the above

  • Prescribed optimal medical therapy

  • AHA exercise and training guidelines classification B and C

  • Willing to give written informed consent

Exclusion Criteria:
  • History of any other chronic illness

  • AHA exercise and training guidelines classification class D

  • Suffer any physical condition for which exercise is a contra-indication

  • Participation in two or more periods of planned moderate intensity exercise per week during the past 6 months

  • Participation in another research study within the previous 60 days

  • History of psychiatric illness

  • Unwilling to give written informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 National Heart and Lung Institute, Imperial College London London United Kingdom SW3 6LY

Sponsors and Collaborators

  • National Heart and Lung Institute
  • British Heart Foundation
  • Royal Brompton & Harefield NHS Foundation Trust

Investigators

  • Principal Investigator: Peter Collins, MA, MD, FRCP, National Heart and Lung Institute, Imperial College London
  • Principal Investigator: Kim Fox, MD, FRCP, Royal Brompton & Harefield NHS Foundation Trust
  • Principal Investigator: Mahmud Barbir, FRCP, Royal Brompton & Harefield NHS Foundation Trust

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Prof. Peter Collins, Professor of Clinical Cardiology, National Heart and Lung Institute
ClinicalTrials.gov Identifier:
NCT00411359
Other Study ID Numbers:
  • 06/Q0404/77
  • PG/06/087/21239
First Posted:
Dec 14, 2006
Last Update Posted:
Apr 22, 2015
Last Verified:
Apr 1, 2015
Keywords provided by Prof. Peter Collins, Professor of Clinical Cardiology, National Heart and Lung Institute
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 22, 2015